Clincosm LogoSign in Get a demo

Diffuse Large B-Cell Lymphoma

Showing 26 - 50 of 231
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ovarian Reserve in Younger Newly Diagnosed Lymphomas

Active, not recruiting
  • Anaplastic Large Cell Lymphoma
  • +4 more
  • Laboratory Biomarker Analysis
  • Questionnaire Administration
  • Birmingham, Alabama
  • +106 more
Jan 11, 2023

Diffuse Large B-cell Lymphoma Trial in Worldwide (Epcoritamab, Investigator's Choice Chemotherapy)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Epcoritamab
  • Investigator's Choice Chemotherapy
  • Irvine, California
  • +254 more
Jan 9, 2023

Diffuse Large B-cell Lymphoma Trial in Worldwide (MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • MB-CART2019.1
  • R-GemOx or BR plus polatuzumab vedotin
  • Graz, Austria
  • +55 more
Jan 5, 2023

NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)

Recruiting
  • Non-small Cell Lung Cancer
  • +11 more
  • Birmingham, Alabama
  • +32 more
Jan 4, 2023

Diffuse Large B-cell Lymphoma Trial in Hangzhou, Ningbo (CD19-7×19 CAR-T combined with Tislelizumab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • CD19-7×19 CAR-T combined with Tislelizumab
  • Hangzhou, Zhejiang, China
  • +1 more
Dec 12, 2022

DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Loncastuximab Tesirine
  • (no location specified)
Dec 13, 2022

Communication Skills Intervention to Promote Transition Into

Active, not recruiting
  • Hodgkin's Lymphoma
  • Diffuse Large B-cell Lymphoma
    • Tampa, Florida
    • +8 more
    Dec 19, 2022

    Multiple Myeloma, DLBCL, Glioblastoma Multiforme Trial in Worldwide (CC-223)

    Completed
    Has Results
    • Multiple Myeloma
    • +6 more
    • Los Angeles, California
    • +15 more
    Dec 9, 2022

    Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)

    Active, not recruiting
    • Diffuse Large B-cell Lymphoma
    • Shanghai, Shanghai, China
      Shanghai Ruijin Hospital
    Dec 1, 2022

    Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma Trial in Seattle (Allogeneic Hematopoietic

    Recruiting
    • Acute Lymphoblastic Leukemia
    • +16 more
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • +4 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Dec 1, 2022

    DLBCL, DLBCL Trial in Worldwide (Zilovertamab vedotin, Rituximab, Gemcitabine)

    Recruiting
    • DLBCL
    • Diffuse Large B-Cell Lymphoma
    • Zilovertamab vedotin
    • +4 more
    • Whittier, California
    • +21 more
    Nov 30, 2022

    DLBCL Trial in Worldwide (Polatuzumab Vedotin, Rituximab, Cyclophosphamide)

    Active, not recruiting
    • Diffuse Large B-Cell Lymphoma
    • Polatuzumab Vedotin
    • +7 more
    • Birmingham, Alabama
    • +242 more
    Nov 23, 2022

    Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial

    Active, not recruiting
    • Acute Leukemia
    • +14 more
    • Duarte, California
      City of Hope Medical Center
    Nov 18, 2022

    DLBCL, Chronic Lymphocytic Leukemia, B Cell Malignancies Trial in Australia, United States (ABBV-525)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • +3 more
    • Louisville, Kentucky
    • +6 more
    Nov 14, 2022

    B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma Trial in Canada, Japan (CTL019)

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • Diffuse Large B-cell Lymphoma
    • CTL019
    • Hamilton, Ontario, Canada
    • +41 more
    Oct 17, 2022

    Diffuse Large B-cell Lymphoma Trial in Wuhan (Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • Mitoxantrone Hydrochloride Liposome
    • +2 more
    • Wuhan, Hubei, China
      Department of Hematology Tongji Hospital, Tongji Medical College
    Oct 7, 2022

    Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)

    Completed
    Has Results
    • Hodgkin Lymphoma
    • Diffuse Large B-Cell Lymphoma
    • Campath
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Sep 11, 2022

    Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma Trial in Nashville (Telemedicine Visit, Vital sign measurements,

    Recruiting
    • Large B-cell Lymphoma
    • Diffuse Large B-cell Lymphoma
    • Telemedicine Visit
    • +3 more
    • Nashville, Tennessee
      Vanderbilt-Ingram Cancer Center
    Sep 28, 2022

    Adult Patients Who Initiate Systemic Treatment for

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • Non-Interventional
    • Graz, Austria
    • +8 more
    Sep 19, 2022

    Tisagenlecleucel in Brazilian Acute Lymphoblastic Leukemia or

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • Acute Lymphoblastic Leukemia
    • tisagenlecleucel
    • (no location specified)
    Sep 13, 2022

    Among Patients Treated With Tisagenlecleucel

    Completed
    • Diffuse Large B-cell Lymphoma
    • Tisagenlecleucel
    • East Hanover, New Jersey
      Novartis Investigative Site
    Sep 13, 2022

    Diffuse Large B-cell Lymphoma Trial in Worldwide (Tafasitamab, Lenalidomide, Rituximab)

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Birmingham, Alabama
    • +408 more
    Aug 23, 2022

    DLBCL, High Grade B-Cell Lymphoma Trial in United States (Venetoclax, Rituximab, Etoposide)

    Completed
    • Diffuse Large B-Cell Lymphoma
    • High Grade B-Cell Lymphoma
    • Boston, Massachusetts
    • +5 more
    Aug 23, 2022

    DLBCL, Chronic Lymphocytic Leukemia, Follicular Lymphoma Trial in New Haven, Worcester, Dallas (ABBV-319)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • +2 more
    • New Haven, Connecticut
    • +2 more
    Aug 22, 2022

    Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

    Recruiting
    • Lymphoma
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 20, 2022